Dose-ranging study of a single injection of pneumococcal conjugate vaccine (1×, 2×, or 4×) in healthy subjects aged 70 years or older

Vesikari, 2009, Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine, Pediatr Infect Dis J, 28, S66, 10.1097/INF.0b013e318199f8ef Black, 2000, Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children, Pediatr Infect Dis J, 19, 187, 10.1097/00006454-200003000-00003 Scott, 2007, Phase 1 trial of a 13-valent pneumococcal conjugate vaccine in healthy adults, Vaccine, 25, 6164, 10.1016/j.vaccine.2007.06.004 Scott, 2008, Phase 1 trial of 13-valent pneumococcal conjugate vaccine in Japanese adults, Pediatr Int, 50, 295, 10.1111/j.1442-200X.2008.02593.x Pebody, 2005, Pneumococcal vaccination policy in Europe, Euro Surveill, 10, 174, 10.2807/esm.10.09.00564-en Whitney, 2003, Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine, N Engl J Med, 348, 1737, 10.1056/NEJMoa022823 Black, 2004, Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente, Pediatr Infect Dis J, 23, 485, 10.1097/01.inf.0000129685.04847.94 Black, 2001, Postlicensure evaluation of the effectiveness of seven valent pneumococcal conjugate vaccine, Pediatr Infect Dis J, 20, 1105, 10.1097/00006454-200112000-00002 Centers for Disease Control and Prevention, 2005, Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease—United States, 1998–2003, MMWR Morb Mortal Weekly Rep, 54, 893 Pilishvili, 2010, Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine, J Infect Dis, 201, 32, 10.1086/648593 Pletz, 2008, Pneumococcal vaccines: mechanism of action, impact on epidemiology and adaption of the species, Int J Antimicrob Agents, 32, 199, 10.1016/j.ijantimicag.2008.01.021 Centers for Disease Control and Prevention, 1997, Prevention of pneumococcal disease: recommendations of the Advisory Committee on Imnunization Practices (ACIP), MMWR Recomm Rep, 46, 1 Melegaro, 2004, The 23-valent pneumococcal polysaccharide vaccine. Part I. Efficacy of PPV in the elderly: a comparison of meta-analyses, Eur J Epidemiol, 19, 353, 10.1023/B:EJEP.0000024701.94769.98 Moberley, 2008, Vaccines for preventing pneumococcal infection in adults, Cochrane Database Syst Rev, 1, CD000422 Rubins, 1998, Magnitude, duration, quality, and function of pneumococcal vaccine responses in elderly adults, J Infect Dis, 178, 431, 10.1086/515644 Brandao, 2004, Persistence of antibody response to pneumococcal capsular polysaccharides in vaccinated long term-care residents in Brazil, Vaccine, 23, 762, 10.1016/j.vaccine.2004.07.024 Konradsen, 1995, Quantity and avidity of pneumococcal antibodies before and up to five years after pneumococcal vaccination of elderly persons, Clin Infect Dis, 21, 616, 10.1093/clinids/21.3.616 Torling, 2003, Revaccination with the 23-valent pneumococcal polysaccharide vaccine in middle-aged and elderly persons previously treated for pneumonia, Vaccine, 22, 96, 10.1016/S0264-410X(03)00521-8 Jackson, 1999, Safety of revaccination with pneumococcal polysaccharide vaccine, JAMA, 281, 243, 10.1001/jama.281.3.243 de Roux, 2008, Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory, Clin Infect Dis, 46, 1015, 10.1086/529142 Jackson, 2007, Immunogenicity of varying dosages of 7-valent pneumococcal polysaccharide-protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine, Vaccine, 25, 4029, 10.1016/j.vaccine.2007.02.062 Dransfield, 2009, Superior immune response to protein-conjugate versus free pneumococcal polysaccharide vaccine in chronic obstructive pulmonary disease, Am J Respir Crit Care Med, 180, 499, 10.1164/rccm.200903-0488OC Manoff, 2010, Revaccination with a 23-valent pneumococcal polysaccharide vaccine induces elevated and persistent functional antibody responses in adults aged ≥65 years, J Infect Dis, 201, 525, 10.1086/651131 Musher, 2010, Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adults, J Infect Dis, 201, 516, 10.1086/649839 Ahmed, 1996, Effect of human immunodeficiency virus type 1 infection on the antibody response to a glycoprotein conjugate pneumococcal vaccine: results from a randomized trial, J Infect Dis, 173, 83, 10.1093/infdis/173.1.83 Feikin, 2002, Randomized trial of the quantitative and functional antibody responses to a 7-valent pneumococcal conjugate vaccine and/or 23-valent polysaccharide vaccine among HIV-infected adults, Vaccine, 20, 545 Kamboj, 2003, Significant variation in serotype-specific immunogenicity of the seven-valent Streptococcus pneumoniae capsular polysaccharide–CRM197 conjugate vaccine occurs despite vigorous T cell help induced by the carrier protein, J Infect Dis, 187, 1629, 10.1086/374785 Kroon, 2001, Enhanced antibody response to pneumococcal polysaccharide vaccine after prior immunization with conjugate pneumococcal vaccine in HIV-infected adults, Vaccine, 19, 886 Powers, 1996, Reactogenicity and immunogenicity of a protein-conjugated pneumococcal oligosaccharide vaccine in older adults, J Infect Dis, 173, 1014, 10.1093/infdis/173.4.1014 Shelly, 1997, Comparison of pneumococcal polysaccharide and CRM197-conjugated pneumococcal oligosaccharide vaccines in young and elderly adults, Infect Immun, 65, 242, 10.1128/IAI.65.1.242-247.1997 Goldblatt, 2009, The immunogenicity of 7-valent pneumococcal conjugate vaccine versus 23-valent polysaccharide vaccine in adults aged 50–80 years, Clin Infect Dis, 49, 1318, 10.1086/606046 Deloria-Knoll, 2006, Effect of zinc and vitamin A supplementation on antibody responses to a pneumococcal conjugate vaccine in HIV-positive injection drug users: a randomized trial, Vaccine, 24, 1670, 10.1016/j.vaccine.2005.09.047 Chan, 1996, Pneumococcal conjugate vaccine primes for antibody responses to polysaccharide pneumococcal vaccine after treatment of Hodgkin's disease, J Infect Dis, 173, 256, 10.1093/infdis/173.1.256 Wuorimaa, 2001, Tolerability and immunogenicity of an 11-valent pneumococcal conjugate vaccine in 9 adults, Vaccine, 19, 1863, 10.1016/S0264-410X(00)00441-2 Quataert, 2004, Assignment of weight-based antibody units for 13 serotypes to a human antipneumococcal standard reference serum, lot 89-S(f), Clin Diagn Lab Immunol, 11, 1064, 10.1128/CDLI.11.6.1064-1069.2004 Hu, 2005, Approach to validating an opsonophagocytic assay for Streptococcus pneumoniae, Clin Diagn Lab Immunol, 12, 287, 10.1128/CDLI.12.2.287-295.2005 Paradiso PR, Gruber WC. The potential of pneumococcal conjugate vaccine in adults. Presented at: 6th International Symposium on Pneumococci and Pneumococcal Diseases. Poster presentation, June 8–12, 2008. Reykjavik, Iceland. Schmöle-Thoma, 2006, Opsonophagocytic responses to pneumococcal conjugate vaccine in the elderly MacLennan, 1999, Immune response to revaccination with meningococcal A and C polysaccharides in Gambian children following repeated immunisation during early childhood, Vaccine, 17, 3086, 10.1016/S0264-410X(99)00139-5 Granoff, 2007, Reconsideration of the use of meningococcal polysaccharide vaccine, Pediatr Infect Dis J, 26, 716, 10.1097/INF.0b013e3180cc2c25 Granoff, 1998, Induction of immunologic refractoriness in adults by meningococcal C polysaccharide vaccination, J Infect Dis, 178, 870, 10.1086/515346 Richmond, 2000, Meningococcal C polysaccharide vaccine induces immunologic hyporesponsiveness in adults that is overcome by meningococcal C conjugate vaccine, J Infect Dis, 181, 761, 10.1086/315284 Borrow, 2001, Influence of prior meningococcal C polysaccharide vaccination on the response and generation of memory after meningococcal C conjugate vaccination in young children, J Infect Dis, 184, 377, 10.1086/322024 Greene, 2006, Preventability of invasive pneumococcal disease and assessment of current polysaccharide vaccine recommendations for adults: United States, 2001–2003, Clin Infect Dis, 43, 141, 10.1086/505117 Metersky, 2010, Determining the optimal pneumococcal vaccination strategy for adults: is there a role for the pneumococcal conjugate vaccine?, Chest, 138, 486, 10.1378/chest.10-0738